STOCK TITAN

Dexcom (NASDAQ: DXCM) officer keeps 101,502 shares after tax withholding

(Moderate)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

DEXCOM INC (DXCM) reported that executive officer Michael Jon Brown had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This was not an open-market sale. After this withholding, Brown directly holds 101,502 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest in tranches from March 8, 2024 through March 8, 2029.

Positive

  • None.

Negative

  • None.
Insider Brown Michael Jon
Role EVP Chief Legal Compliance Off
Type Security Shares Price Value
Tax Withholding Common Stock F1, F2 1,451 $92.34 $134K
Holdings After Transaction: Common Stock — 101,502 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
  2. F2. Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Shares withheld for tax 1,451 shares Withheld on August 22, 2026 to cover tax obligations on RSU net settlement
Withholding price per share $92.34 per share Price applied to the 1,451 shares withheld for tax obligations
Shares held after transaction 101,502 shares Direct holdings of Dexcom common stock by Michael Jon Brown after withholding
Total unvested restricted stock units 71,903 units Unvested RSUs included in the post-transaction holdings
RSUs granted March 8, 2026 39,019 units Unvested RSUs vesting through March 8, 2029
RSUs granted March 8, 2025 (2028 tranche) 19,948 units Unvested RSUs vesting through March 8, 2028
RSUs granted March 8, 2025 (2027 tranche) 5,699 units Unvested RSUs vesting through March 8, 2027
RSUs granted March 8, 2024 7,237 units Unvested RSUs vesting through March 8, 2027
restricted stock units financial
"in connection with the net settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
net settlement financial
"in connection with the net settlement of restricted stock units"
tax withholding and remittance obligations financial
"to cover tax withholding and remittance obligations in connection"

FAQ

What insider transaction did DXCM executive Michael Jon Brown report?

Michael Jon Brown reported that 1,451 shares of Dexcom common stock were withheld on August 22, 2026 to satisfy tax withholding and remittance obligations related to restricted stock units. The company states this event does not represent a sale by Brown.

How many DXCM shares does Michael Jon Brown hold after this transaction?

After the August 22, 2026 tax withholding transaction, Michael Jon Brown directly holds 101,502 shares of Dexcom common stock. This figure includes both vested shares and 71,903 unvested restricted stock units scheduled to vest over multiple future dates.

Was the reported DXCM insider transaction an open-market sale?

No. Dexcom states the 1,451 shares were required to be withheld by the company to cover tax withholding and remittance obligations from the net settlement of restricted stock units and that it does not represent a sale by Michael Jon Brown.

What unvested restricted stock units does Michael Jon Brown have at DXCM?

Michael Jon Brown has 71,903 unvested restricted stock units, including 39,019 granted March 8, 2026 vesting through March 8, 2029; 19,948 granted March 8, 2025 vesting through March 8, 2028; 5,699 granted March 8, 2025 vesting through March 8, 2027; and 7,237 granted March 8, 2024 vesting through March 8, 2027.

At what price were the DXCM shares withheld for taxes in this filing?

The 1,451 shares of Dexcom common stock withheld on August 22, 2026 are reported at $92.34 per share, in connection with covering tax withholding and remittance obligations from the net settlement of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brown Michael Jon

(Last)(First)(Middle)
6340 SEQUENCE DRIVE

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP Chief Legal Compliance Off
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/22/2026F1,451(1)D$92.34101,502(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
2. Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Remarks:
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)